Articles

Promega will demonstrate applications of bioluminescence tools at Discover Glo 2021.

Promega to Showcase Applications of Bioluminescent Research Tools at Global Seminar Series

Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.

Partnership Forms for Development of Inhalable Formulation to Treat Lung Cancer, Lung Fibrosis, and SARS-CoV-2 

Aptamer Group and Bio-Works Technologies are partnering up to develop a new affinity resin for improved purification and scale-up of gene therapy vectors. 

Aptamer Group, Bio-Works Technologies Collaborate on Affinity Resin for Gene Therapy Manufacturing

MHRA has approved Scancell’s clinical trial application for the initiation of the first-in-human Phase I/II study of Modi-1—a therapeutic vaccine candidate from the company's Moditope platform.

MHRA Approves Clinical Trial Application for Scancell’s Modi-1

CC Bio has raised £890,000 (US $1.2 million) in seed funding from CMS Ventures to accelerate the development of an innovative approach to infection treatment and prevention.

CC Bio Gains Seed Funding Boost from CMS Ventures

AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.

AGC Biologics Breaks Ground on New Multipurpose Facility in Denmark

Todos Medical has completed validation of its cPass neutralizing antibody blood test to monitor COVID-19 immunity.

Todos Medical to Launch New Antibody Blood Test for COVID-19

NGM Biopharmaceuticals has disclosed a fourth antibody drug candidate, NGM831, for development into an oncology therapeutic.

NGM Bio Pinpoints Fourth Antibody Drug Candidate for Oncology Therapy Development

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

Pfizer to Acquire Trillium Therapeutics in $2.26-Billion Deal

Lonza plans to establish drug product manufacturing capabilities at is site in Guangzhou, China, to produce clinical trial and commercial supply in the country.

News